The graft with the maximum osteogenic potential is:
A researcher is studying the interactions between foreign antigens and human immune cells. She has isolated a line of lymphocytes that is known to bind antigen-presenting cells. From this cell line, she has isolated a cell surface protein that binds to class I major histocompatibility complex molecules. The continued activation, proliferation and survival of this specific cell line requires which of the following signaling molecules?
All of the following factors affect osseointegration EXCEPT:
The hypersensitivity reaction involved in the hyperacute rejection of a renal transplant is:
What is the consequence of preformed antibodies in organ transplantation?
An autograft of a burn victim is best described by which one of the following?
Compression osteosynthesis may be used in all these areas except?
All are true about aneurysmal bone cyst except -
Which of the following is the POOREST recipient bed for a skin graft?
The ideal synthetic material used for femoropopliteal bypass when autologous vein is unavailable is:
Explanation: ***autocancellus*** - **Autocancellous** bone grafts are considered the gold standard due to their high osteogenic potential as they contain **viable osteoblasts** and **bone marrow stromal cells**. - The porous structure of cancellous bone also provides a **scaffold** for new bone formation and excellent revascularization. *Allograft* - **Allografts** are grafts transferred between genetically dissimilar individuals of the same species and are **osteoconductive** and **osteoinductive** but lack viable cells and thus have lower osteogenic potential than autografts. - They undergo sterilization processes that can further reduce their osteoinductive properties and may elicit an **immune response** from the recipient. *xenograft* - **Xenografts** are grafts transferred between different species and primarily serve as an **osteoconductive scaffold**. - They lack live osteogenic cells and have the **lowest osteogenic potential** due to significant immunological barriers and species-specific biochemical differences. *Autocortical* - **Autocortical** grafts are structural and provide mechanical support, but their **osteogenic potential is lower** than cancellous bone. - Cortical bone has a denser structure with fewer viable cells and a slower revascularization rate compared to cancellous bone.
Explanation: ***Interleukin 2*** - The description of the lymphocyte binding the **constant portion of MHC class I** and requiring a signaling molecule for activation, proliferation, and survival points to a **T cell**. - **Interleukin-2 (IL-2)** is a crucial cytokine for the proliferation, differentiation, and survival of T lymphocytes, acting in an autocrine or paracrine fashion after T cell activation. *Interleukin 1* - **Interleukin-1 (IL-1)** is primarily involved in inflammation and fever, produced by macrophages and other innate immune cells. - While it can act as a costimulator for T cells, it is not the primary cytokine required for their sustained proliferation and survival after initial activation. *Interleukin 4* - **Interleukin-4 (IL-4)** is a key cytokine in humoral immunity, promoting B cell proliferation and differentiation, and inducing IgE class switching. - It also plays a role in the differentiation of naive T cells into **Th2 cells**, but it is not the main cytokine for general T cell proliferation and survival. *Interleukin 8* - **Interleukin-8 (IL-8)**, also known as CXCL8, is a chemokine primarily responsible for attracting and activating neutrophils to sites of infection or inflammation. - It does not have a direct role in the sustained proliferation and survival of activated lymphocytes. *Interleukin 6* - **Interleukin-6 (IL-6)** is a pleiotropic cytokine involved in acute phase reactions, hematopoiesis, and the immune response, particularly B cell differentiation and antibody production. - Although it can influence T cell responses, it is not the primary growth factor for activated T lymphocytes as IL-2 is.
Explanation: ***Patient's blood type*** - A patient's **blood type** (e.g., A, B, AB, O) is determined by antigens present on red blood cells and plays no direct role in the biological processes of bone healing or the integration of a dental implant with bone. - While systemic factors can influence osseointegration, blood type itself does not affect the cellular and molecular mechanisms required for direct bone-to-implant contact. *Biocompatibility of implant material* - The **biocompatibility** of the implant material (e.g., **titanium**) is crucial for osseointegration, as it must not elicit adverse reactions and must permit host bone growth on its surface. - Materials that are cytotoxic or inflammatory will prevent bone apposition and lead to fibrous encapsulation rather than direct bone contact. *Implant design* - **Implant design**, including features like **surface roughness**, thread pitch, and macro-geometry, significantly influences the initial stability and long-term success of osseointegration. - A greater surface area and appropriate surface treatments can enhance bone cell attachment and differentiation, promoting faster and stronger bone integration. *Status of the host bed* - The **status of the host bone bed** refers to its quality and quantity (e.g., bone density, vascularity), which are critical for the biological processes of osseointegration. - Adequate bone volume and good bone quality provide a stable foundation and sufficient blood supply for bone regeneration around the implant.
Explanation: ***Type II*** - Hyperacute rejection is primarily mediated by **antibody-mediated mechanisms**, indicative of Type II hypersensitivity [2]. - It involves pre-existing **IgG antibodies** that react against donor renal graft antigen, leading to rapid graft destruction [1]. *Type I* - Type I hypersensitivity is associated with **allergic reactions** involving **IgE antibodies**, not relevant to transplant rejection [2]. - Typically involves conditions like **anaphylaxis** or **asthma**, which are unrelated to hyperacute rejection scenarios. *Type IV* - Type IV hypersensitivity is cell-mediated and typically manifests as **delayed-type hypersensitivity**, not acute rejection. - It involves **T cells** and does not play a role in the immediate immune response seen in hyperacute rejection. *Type III* - Type III hypersensitivity involves the formation of immune complexes, leading to conditions like **serum sickness**, not hyperacute rejection. - This type of reaction is usually more relevant in **chronic inflammatory conditions** rather than immediate transplant rejections. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 241-242. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 208-210.
Explanation: ***Hyperacute rejection*** - This occurs immediately after transplant due to **preformed antibodies** reacting against donor antigens, leading to rapid allograft failure [1]. - It is typically associated with **complement activation** and often results in thrombosis of the graft vessels [1]. *Acute rejection* - Primarily mediated by **T cells** rather than preformed antibodies, occurring days to months after transplantation [2]. - Involves a **cellular immune response**, unlike hyperacute rejection which is antibody-mediated [2]. *Acute humoral rejection* - Also involves antibodies but develops **days to weeks** post-transplant rather than immediately like hyperacute rejection. - This type is characterized by a **specific antibody response** and complement activation, but is not due to preformed antibodies. *Chronic rejection* - A long-term process that develops over months to years due to **persistent immune-mediated injury** to the graft, leading to gradual loss of function. - Involves mechanisms such as **tissue fibrosis and vascular changes**, differing from the immediate action of preformed antibodies in hyperacute rejection. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 241-242. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 242.
Explanation: ***Transplant from one region of a person to another region*** - An **autograft** involves transferring tissue from one site to another within the **same individual**. - This type of graft is immunologically optimal as it avoids **immune rejection**. *Transplant from one person to another person* - This describes an **allograft**, where tissue is transplanted between genetically distinct individuals of the **same species**. - **Allografts** carry a risk of rejection and require immunosuppression. *Transplant from one person to a genetically identical person* - This is an **isograft** (or syngraft), occurring between **monozygotic twins** or highly inbred animals. - While genetically identical, it is a specific type of **allograft** and not an autograft. *Transplant from one species to another species* - This describes a **xenograft**, where tissue is transferred between individuals of **different species**. - **Xenografts** face significant immune rejection and ethical considerations, making them less common in standard practice.
Explanation: ***Comminuted fractures of the mandible*** - **Compression osteosynthesis** is generally **contraindicated** in comminuted fractures because the application of compression can further **displace or fragment** the multiple bone pieces. - Such fractures often require **tension band plating** or **reconstruction plates** to stabilize the fragments without causing additional compression or displacement. *FZ suture (provides anatomical support)* - The **frontozygomatic (FZ) suture** is an area where compression osteosynthesis can be effectively used to achieve **stable fixation** and **anatomical reduction**. - Compression helps to **stabilize the bone segments** at the suture line, leading to better healing and restoration of orbital rim integrity. *Bone graft fixation (promotes healing)* - Compression osteosynthesis is often employed in **bone graft fixation** to promote **intimate contact** between the graft and the host bone, which is crucial for successful **graft incorporation and healing**. - This compression enhances **vascularization** and reduces movement, creating a more favorable environment for **osteogenesis**. *Root of zygomatic arch (maintains structural integrity)* - Compression osteosynthesis can be effectively used at the **root of the zygomatic arch** to maintain **structural integrity** and achieve stable fixation of fractures in this region. - Applying compression helps to **reduce fracture gaps** and provides stability, which is essential for restoring the contour and function of the midface.
Explanation: ***Treated by simple curettage*** - Aneurysmal bone cysts (ABCs) often require more aggressive treatment than simple curettage due to their **high recurrence rate** and the risk of incomplete removal. - **Sclerotherapy**, **embolization**, or **en bloc resection** may be necessary, especially for larger or recurrent lesions, as simple curettage alone is often insufficient. *Eccentric* - Aneurysmal bone cysts are indeed **eccentric lesions**, meaning they are located off-center within the bone. - This eccentric location is a characteristic feature often observed on **radiological imaging**. *Expansile & lytic* - ABCs are typically **expansile** (causing bone expansion) and **lytic** (destructive to bone tissue) lesions. - This combination of features contributes to the characteristic **"blow-out" appearance** on imaging. *Metaphysis of long bones* - The **metaphysis of long bones** is a common site for aneurysmal bone cysts, particularly in younger individuals. - Other frequently affected sites include the **spine** and **flat bones**.
Explanation: ***Fat*** - **Fat** is a poor recipient for a skin graft due to its **limited vascularity**, which hinders the necessary process of revascularization for graft survival. - The high metabolic demand of a graft cannot be adequately met by the relatively avascular subcutaneous fat, leading to graft failure. *Muscle* - **Muscle tissue** is an excellent recipient bed for skin grafts due to its **rich blood supply**. - Its robust vascularity effectively supports the revascularization and survival of the grafted tissue. *Deep fascia* - **Deep fascia** provides a good vascularized bed for skin grafts, as it has a reasonable blood supply from underlying muscles and surrounding tissues. - This vascularization is sufficient to nourish and ensure the take of a skin graft. *Skull bone* - **Skull bone** (specifically the periosteum covering it) can serve as an adequate graft bed due to its vascular supply. - If the **periosteum** is intact and healthy, it offers sufficient blood flow for graft survival.
Explanation: ***ePTFE (Expanded Polytetrafluoroethylene)*** - **ePTFE** is the preferred synthetic graft for femoropopliteal bypass when autologous vein is unavailable - Offers good **biocompatibility** and relative resistance to **thrombosis** - Provides superior patency rates in above-knee femoropopliteal bypasses compared to other synthetic materials (5-year patency ~50-60%) - The expanded structure allows tissue ingrowth and better integration *Dacron (Polyethylene terephthalate)* - Generally used for **larger diameter vessels** (e.g., aortoiliac grafts) - Has **inferior patency rates** in smaller diameter femoropopliteal position compared to ePTFE - More prone to kinking and associated with higher rates of intimal hyperplasia in peripheral circulation *Saphenous vein* - The autologous saphenous vein is the **gold standard** for femoropopliteal bypass with superior long-term patency (5-year patency ~70-80%) - However, this question specifically asks for synthetic material when vein is unavailable or unsuitable - Not always available or of adequate quality in all patients *PTFE (non-expanded)* - **Non-expanded PTFE** lacks the porous structure of ePTFE - Not used for vascular grafts due to absence of tissue ingrowth capability - The **expanded** form is specifically engineered for vascular applications
Get full access to all questions, explanations, and performance tracking.
Start For Free